<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="20551">5-aminosalicylates</z:chebi> are extensively prescribed for the treatment of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> but have a wide range of described adverse effects </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: To determine whether serious adverse effect profiles differ for sulphasalazine and <z:chebi fb="0" ids="6775">mesalazine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Analysis of suspected serious adverse reactions reported to the Committee on Safety of Medicines of the UK in 1991-1998 </plain></SENT>
<SENT sid="3" pm="."><plain>Adverse effect profiles were categorised for <z:hpo ids='HP_0001970'>interstitial nephritis</z:hpo>, <z:hpo ids='HP_0001733'>pancreatitis</z:hpo>, serious skin reactions, <z:hpo ids='HP_0012115'>hepatitis</z:hpo> and <z:hpo ids='HP_0001399'>hepatic failure</z:hpo>, and <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood dyscrasias</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Report rates were calculated using prescribing data from the Department of Health and compared for <z:chebi fb="0" ids="6775">mesalazine</z:chebi> and sulphasalazine </plain></SENT>
<SENT sid="5" pm="."><plain>Further analysis was undertaken for sulphasalazine according to disease indication of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> or <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: A total of 4.7 million prescriptions were dispensed for sulphasalazine compared with 2.8 million for <z:chebi fb="0" ids="6775">mesalazine</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001970'>Interstitial nephritis</z:hpo> was only described for <z:chebi fb="0" ids="6775">mesalazine</z:chebi>, with 11.1 reports per million prescriptions </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0001733'>Pancreatitis</z:hpo> was reported seven times as frequently for <z:chebi fb="0" ids="6775">mesalazine</z:chebi> (7.5 per million prescriptions) compared with sulphasalazine (1.1 per million prescriptions) (odds ratio (OR) 7.0; 95% confidence interval (CI) 2.6-18.6; p&lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>There were no reports of serious <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">skin disorders</z:e> in patients prescribed sulphasalazine for <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">Blood dyscrasias</z:e> were reported significantly more often in patients receiving sulphasalazine for <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> than for <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (OR 5.31; 95% CI 2.6-11.0; p&lt;0.001), and there was a similar trend for <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic disorders</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Spontaneous reports suggest that within the five sets of disorders considered, there is no evidence to indicate a safety advantage of <z:chebi fb="0" ids="6775">mesalazine</z:chebi> over sulphasalazine in the treatment of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0001733'>Pancreatitis</z:hpo> and <z:hpo ids='HP_0001970'>interstitial nephritis</z:hpo> appear significantly more common with <z:chebi fb="0" ids="6775">mesalazine</z:chebi>, and advice on renal monitoring in patients who receive <z:chebi fb="0" ids="6775">mesalazine</z:chebi> may need reinforcing </plain></SENT>
</text></document>